Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Michael Moore Gives Sicko New Life

This article was originally published in The Pink Sheet Daily

Executive Summary

Filmmaker has heightened his focus on a documentary looking at the American health care system, including the drug industry. Handicapping of Fahrenheit 9/11's chances in the Oscar race appears to be one factor behind renewing work on the project.

You may also be interested in...



Prozac Documents Deemed "Missing" Were Already Available, Lilly Says

The documents which appeared in the British Medical Journal were shared with FDA, published in medical journals or produced through legal discovery over 10 years ago, Lilly says. The company maintains the medical journal "published data without validating the information."

Filmmaker Moore's Look At Pharma On Backburner?

Michael Moore's plans for a Fahrenheit 9/11 sequel in time for the next presidential race may delay work on Sicko, his expected documentary on the U.S. health care system. The film is understood to remain in the earliest stages of development due to an absence of financial backing.

Endo’s Lidoderm Mailings Draw FDA Warning Letter For Unsubstantiated Claims

FDA asks Endo to disseminate “corrective messages” to doctors who received the violative promotional materials, which the agency says omit risk information and contain unsubstantiated effectiveness claims.

Topics

UsernamePublicRestriction

Register

MT142539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel